Why Truvada isn't being used for HIV prevention

Share this article:

On the penultimate day of 2013, the New York Times gave readers a deep dive on Gilead's Truvada for use in preventing HIV, or rather the lack thereof. As the Times notes, the combo drug has seen poor uptake among the gay community for that indication, 18 months after the strategy's FDA approval.

The lack of Truvada prescriptions—particularly among men—was attributed in part to “negative reactions” HCPs have reportedly given men when they brought it up, as well as social stigma: a particularly derogatory label has been used on social networks to describe men who are on the pill and purposefully engaging in risky behavior, NYT reports.

The article also addressed the absence of a public campaign to promote Truvada for prevention, its price, and side effects. Adherence issues, too, were called out.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.